Advertisement

Topics

Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma

02:57 EST 20 Feb 2019 | Pharmaceutical Business Review

The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks

The post Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma appeared first on Pharmaceutical Business review.

Original Article: Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma

NEXT ARTICLE

More From BioPortfolio on "Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....